Stocktwits on MSN
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study
The trial was conducted by Sagimet’s license partner for China, Ascletis Bioscience Co., in 480 patients with moderate to ...
Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase 3 trial for moderate to severe acne vulgaris. The trial was conducted by ...
ORLANDO, Fla. — For decades, patient package inserts for oral isotretinoin, the gold standard of treatment for severe acne, have advised that people avoid undergoing facial resurfacing treatments, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback